JP4323167B2 - 分泌タンパク質を発現する細胞の単離 - Google Patents

分泌タンパク質を発現する細胞の単離 Download PDF

Info

Publication number
JP4323167B2
JP4323167B2 JP2002558477A JP2002558477A JP4323167B2 JP 4323167 B2 JP4323167 B2 JP 4323167B2 JP 2002558477 A JP2002558477 A JP 2002558477A JP 2002558477 A JP2002558477 A JP 2002558477A JP 4323167 B2 JP4323167 B2 JP 4323167B2
Authority
JP
Japan
Prior art keywords
cell
poi
cells
molecule
cell surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002558477A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004520037A (ja
JP2004520037A5 (https=
Inventor
ジェイムズ ピー． ファンドル，
ニール スタール，
ガン チェン，
ジョージ ディー． ヤンコポウロス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2004520037A publication Critical patent/JP2004520037A/ja
Publication of JP2004520037A5 publication Critical patent/JP2004520037A5/ja
Application granted granted Critical
Publication of JP4323167B2 publication Critical patent/JP4323167B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2002558477A 2001-01-16 2002-01-16 分泌タンパク質を発現する細胞の単離 Expired - Lifetime JP4323167B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26199901P 2001-01-16 2001-01-16
PCT/US2002/001208 WO2002057423A2 (en) 2001-01-16 2002-01-16 Isolating cells expressing secreted proteins

Publications (3)

Publication Number Publication Date
JP2004520037A JP2004520037A (ja) 2004-07-08
JP2004520037A5 JP2004520037A5 (https=) 2006-01-05
JP4323167B2 true JP4323167B2 (ja) 2009-09-02

Family

ID=22995765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002558477A Expired - Lifetime JP4323167B2 (ja) 2001-01-16 2002-01-16 分泌タンパク質を発現する細胞の単離

Country Status (9)

Country Link
US (3) US6919183B2 (https=)
EP (1) EP1392859B1 (https=)
JP (1) JP4323167B2 (https=)
AT (1) ATE325865T1 (https=)
AU (1) AU2002245272B2 (https=)
CA (1) CA2434802C (https=)
DE (1) DE60211329T2 (https=)
IL (2) IL156910A0 (https=)
WO (1) WO2002057423A2 (https=)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
US6919183B2 (en) * 2001-01-16 2005-07-19 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
GB0118337D0 (en) * 2001-07-27 2001-09-19 Lonza Biologics Plc Method for selecting antibody expressing cells
JP2005526517A (ja) * 2002-05-22 2005-09-08 バイオジェン・アイデック・エムエイ・インコーポレイテッド 分泌性ポリペプチドの検出
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US7771969B2 (en) 2003-08-20 2010-08-10 Celltech R&D Limited Methods for obtaining antibodies
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
EP2021795A4 (en) 2006-05-04 2009-05-13 Abmaxis Inc CROSS SPECIES AND MULTI-SPECIAL PRESENTATION SYSTEMS
EP2027273B1 (en) 2006-05-17 2016-04-13 F. Hoffmann-La Roche AG Polypeptide producing cells
DK2102239T3 (da) * 2006-11-30 2012-05-29 Res Dev Foundation Forbedrede immunoglobulin-biblioteker
US20090075378A1 (en) * 2007-02-20 2009-03-19 Anaptysbio, Inc. Somatic hypermutation systems
EP2617827A1 (en) 2007-03-26 2013-07-24 Celexion, LLC Method for displaying engineered proteins on a cell surface
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8637435B2 (en) * 2007-11-16 2014-01-28 Merck Sharp & Dohme Corp. Eukaryotic cell display systems
EP2240475B1 (en) 2007-12-20 2013-09-25 Novartis AG Thiazole derivatives used as pi 3 kinase inhibitors
WO2009103753A1 (en) * 2008-02-20 2009-08-27 Ablynx Nv Methods for identifying and/or sorting cells by secreted molecule and kits for performing such methods
JP5731827B2 (ja) 2008-03-03 2015-06-10 グライコフィ， インコーポレイテッド 下等真核生物中での組換えタンパク質の表面ディスプレイ
US8067339B2 (en) * 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
WO2010064748A1 (en) * 2008-12-04 2010-06-10 Korea Research Institute Of Bioscience And Biotechnology Screening of abundantly secreted proteins and their use as fusion partners for the production of recombinant proteins
US8409838B2 (en) 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US8278873B2 (en) * 2009-09-10 2012-10-02 Syntheon, Llc Surgical sterilizer with integrated battery charging device
CA2789446A1 (en) * 2010-02-12 2011-08-18 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
EP2390661B1 (en) * 2010-05-02 2015-06-24 Miltenyi Biotec GmbH An anchoring/capturing means for selecting or analyzing a CHO cell according to a product secreted by the CHO cell
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
US8986956B2 (en) 2010-11-04 2015-03-24 Korea Research Institute Of Bioscience And Biotechnology Method for producing human epidermal growth factor in large volume from yeast
IL210093A0 (en) * 2010-12-19 2011-06-30 David Helman Membrane bound reporter molecules and their use in cell sorting
JP2014504503A (ja) 2010-12-28 2014-02-24 ゾーマ テクノロジー リミテッド Ｐｄｚドメインを用いた細胞表面提示
EP3604339B1 (en) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
MX343706B (es) 2011-01-31 2016-11-18 Novartis Ag Derivados heterocíclicos novedosos.
CN102680679B (zh) * 2011-03-15 2014-08-27 中国科学院上海生命科学研究院 检测单细胞特异性抗体分泌的细胞微孔芯片及其制备方法
PT2771342T (pt) 2011-10-28 2016-08-17 Novartis Ag Derivados de purina e o seu uso no tratamento de doença
EP2847368B1 (en) 2012-05-11 2020-08-19 Merck Sharp & Dohme Corp. Surface anchored light chain bait antibody display system
WO2013173283A1 (en) 2012-05-16 2013-11-21 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
TW202423993A (zh) * 2012-11-14 2024-06-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
US9353163B2 (en) 2013-03-14 2016-05-31 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
KR102243980B1 (ko) 2013-10-11 2021-04-26 리제너론 파마슈티칼스 인코포레이티드 대사적으로 최적화된 세포 배양
CN105979947A (zh) 2013-12-06 2016-09-28 诺华股份有限公司 α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案
AR102333A1 (es) 2014-08-19 2017-02-22 Regeneron Pharma Selectividad eficiente de proteínas recombinadas
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
RU2018119085A (ru) 2015-11-02 2019-12-04 Новартис Аг Схема введения ингибитора фосфатидилинозитол-3-киназы
WO2017132701A1 (en) * 2016-01-31 2017-08-03 Shuang Zhang Method for screening antibodies
EP4414484A3 (en) * 2016-02-04 2025-01-15 Trianni, Inc. Enhanced production of immunoglobulins
WO2017203051A1 (en) 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork An engineered gram positive bacterium
US20200317738A1 (en) 2016-05-26 2020-10-08 University College Cork - National University Of Ireland, Cork Methods for increasing proliferation of mammalian cells
TWI767915B (zh) 2016-06-27 2022-06-21 加州大學董事會 Ror-1與btk拮抗劑的組合
WO2018041740A1 (en) 2016-09-01 2018-03-08 Bayer Pharma Aktiengesellschaft Non-covalent display system using fimgt/dsf
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
CN109790214B (zh) 2016-09-29 2022-09-06 豪夫迈·罗氏有限公司 用于选择产生多肽的细胞的改进方法
GB201703418D0 (en) 2017-03-03 2017-04-19 Ge Healthcare Bio Sciences Ab Method for cell line development
GB201704115D0 (en) * 2017-03-15 2017-04-26 Oxford Genetics Ltd Method of selecting for antibodies
IL312457A (en) 2017-03-24 2024-06-01 Lankenau Inst Medical Res Methods and compositions for inducible extracellular membrane trapping of monoclonal immunoglobulins secreted by hybridomas
EP3673044A1 (en) 2017-08-25 2020-07-01 University College Cork-National University of Ireland, Cork Bifidobacterium longum for treating obesity and weight management
US20200345051A1 (en) 2017-11-24 2020-11-05 University College Cork, National University Of Ireland, Cork A composition comprising a cohort of bacteria
EP3604507A1 (en) 2018-07-30 2020-02-05 University College Cork-National University of Ireland, Cork An omega-transaminase enzyme
WO2020056456A1 (en) * 2018-09-17 2020-03-26 South Australian Health And Medical Research Institute Limited Methods for producing proteins
AU2020256225B9 (en) * 2019-04-03 2025-04-10 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
EP3783012A1 (en) 2019-08-20 2021-02-24 Nuritas Limited An antimicrobial peptide
EP4218787A3 (en) 2019-08-20 2023-12-20 Nuritas Limited Peptides for treating muscle atrophy
JP2022553367A (ja) 2019-10-22 2022-12-22 ニューリタス リミテッド 非アルコール性脂肪肝の治療
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN117015710A (zh) * 2021-03-10 2023-11-07 索尼集团公司 生物粒子分析方法及用于生物粒子分析的试剂盒
EP4070670A1 (en) 2021-04-08 2022-10-12 University College Cork-National University of Ireland Cork Lacticaseibacillus paracasei em025-11 and uses thereof
JP2024514195A (ja) 2021-04-14 2024-03-28 ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド，コーク 脳血管イベントおよび神経障害の治療
US20240197827A1 (en) 2021-04-14 2024-06-20 University College Cork - National University Of Ireland, Cork Psg1 for use in the treatment of osteoarthritis
WO2023059803A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
CA3230984A1 (en) 2021-10-07 2023-04-13 Ross BROWNE Systems and methods of ph modeling and control
CN119301236A (zh) 2022-03-02 2025-01-10 瑞泽恩制药公司 用于抗体生产的生物反应器
CN120379687A (zh) 2022-10-14 2025-07-25 爱尔兰国立科克大学 胎盘表达的蛋白用于治疗肌腱损伤
WO2025133254A2 (en) 2023-12-20 2025-06-26 Nuritas Limited Angiotensin-converting enzyme (ace) inhibiting peptides.
WO2025133189A1 (en) 2023-12-20 2025-06-26 Nuritas Limited Sleep promoting peptides and the use thereof
CN118006552A (zh) * 2024-04-09 2024-05-10 暨南大学 一种抗原特异性浆细胞的筛选方法及其应用
WO2026008665A1 (en) 2024-07-01 2026-01-08 Vib Vzw Binders of the pd-1•pd-l1 complex and their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3731891B2 (ja) * 1992-10-21 2006-01-05 ミルテンイ，ステファン 分泌生成物による細胞の直接選択
US6287784B1 (en) * 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
MX336813B (es) * 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
AU765085B2 (en) * 1998-05-11 2003-09-11 Miltenyi Biotec Gmbh Method of direct selection of antigen-specific T cells
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
DE19900635A1 (de) * 1999-01-11 2000-07-13 Deutsches Krebsforsch Selektion von monoklonalen Antikörpern
US6919183B2 (en) * 2001-01-16 2005-07-19 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins

Also Published As

Publication number Publication date
HK1059290A1 (en) 2004-06-25
EP1392859A2 (en) 2004-03-03
ATE325865T1 (de) 2006-06-15
DE60211329D1 (de) 2006-06-14
JP2004520037A (ja) 2004-07-08
US20020168702A1 (en) 2002-11-14
EP1392859B1 (en) 2006-05-10
DE60211329T2 (de) 2007-05-24
US20050186623A1 (en) 2005-08-25
WO2002057423A2 (en) 2002-07-25
CA2434802A1 (en) 2002-07-25
WO2002057423A3 (en) 2003-12-18
AU2002245272B2 (en) 2006-06-29
IL156910A (en) 2009-08-03
IL156910A0 (en) 2004-02-08
US7435553B2 (en) 2008-10-14
CA2434802C (en) 2013-05-28
US20060234311A1 (en) 2006-10-19
US6919183B2 (en) 2005-07-19
EP1392859A4 (en) 2004-11-24

Similar Documents

Publication Publication Date Title
JP4323167B2 (ja) 分泌タンパク質を発現する細胞の単離
US10598669B2 (en) Isolating cells expressing secreted proteins
US12577326B2 (en) Recombinant cell surface capture proteins
AU2002245272A1 (en) Isolating cells expressing secreted proteins
US20170241887A1 (en) Isolating Cells Expressing Secreted Proteins
US20140072980A1 (en) Isolating cells expressing secreted proteins
HK1059290B (en) Isolating cells expressing secreted proteins
HK1214612B (en) Recombinant cell surface capture proteins
HK1211036B (en) Recombinant cell surface capture proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080221

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080324

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080324

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080417

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081215

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090526

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090604

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4323167

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120612

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130612

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term